Opinion | December 20, 2021
2022: Predictions for medical and healthcare industry
2022 is going to be the year of opportunities and innovations from the medical industry in India
2022 is going to be the year of opportunities and innovations from the medical industry in India
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Biocon Biologics and Viatris co-developed the products
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Subscribe To Our Newsletter & Stay Updated
